Actual Medicinal Product (AMP) Exemestane 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
No special precautions for storage.
- Provenance
-
This compatibility recommendation is derived from Aromasin 25mg tablets (Pfizer Ltd).
- Generic
- Exemestane
- Formulation
- Exemestane 25mg tablets
-
Exemestane
-
Exemestane 25mg tablets
-
Exemestane 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
-
-